The 2023 CBI Index – the ultimate cross-jurisdictional investment tool launched
September 14, 2023
Showcasing the best countries to invest in this year London, Sept. 14, 2023 (GLOBE NEWSWIRE) — Today, the seventh edition
South Africa
Richard Curtis releases new version of famous Al Pacino ‘locker room’ scene to mark that the world is at halftime on Sustainable Development Goals
September 14, 2023
Al Pacino still from ‘Inches (with Al Pacino)| The Global Goals | Halftime 2023’ The world is at ‘Halftime’ when
Richard Curtis lança nova versão da famosa cena do balneário de Al Pacino para salientar que o mundo está no “Intervalo” para alcançar os Objetivos de Desenvolvimento Sustentável
September 14, 2023
Al Pacino still from ‘Inches (with Al Pacino)| The Global Goals | Halftime 2023’ O mundo está no período de
Richard Curtis sort une nouvelle version de la célèbre scène des vestiaires avec Al Pacino pour marquer la mi-temps de l’échéance de réalisation des Objectifs de Développement Durable
September 14, 2023
Al Pacino still from ‘Inches (with Al Pacino)| The Global Goals | Halftime 2023’ Le monde est à la «
Chief Sales Officer of AI-Media Excited to Showcase Subtitling Innovation at Upcoming IBC Broadcast Tradeshow
September 13, 2023
AI-Media Exhibits at IBC 2023 BROOKLYN, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — AI-Media, the leader in technology-driven live captioning
A Curia apoia o ensaio clínico de fase 1 da nova vacina de RNA de última geração da Replicate Bioscience
September 13, 2023
O fornecimento de um fármaco fabricado segundo as normas de BPFa apoia o primeiro estudo clínico em seres humanos do
Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine
September 13, 2023
Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA) ALBANY, N.Y., Sept.
Curia soutient l’essai clinique de phase 1 de Replicate Bioscience sur un vaccin novateur à base d’ARN de nouvelle génération
September 13, 2023
L’entreprise apporte une substance médicamenteuse fabriquée selon les BPFa afin de permettre la première étude clinique chez un être humain